Adtralza
(Tralokinumab)Phase 3Monoclonal antibody
LEO PharmaTralokinumab is used to treat moderate to severe atopic dermatitis (eczema), a skin condition that causes itching, redness, and inflammation. It works by blocking a specific protein in the body that triggers the inflammatory response in the skin.[1] Adtralza is currently being investigated across 4 indications[3], with its most advanced program in Phase 3.[1]
Adtralza is one of 101 monoclonal antibody programs targeting Atopic Dermatitis. It is currently in Phase 3.
4
Indications
30
Total Trials
6
Active Trials
100
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
127 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 3
Fludara
SanofiPhase 3
Adtralza
LEO PharmaPhase 3
Amlitelimab
SanofiPhase 3
DUPIXENT
RegeneronPhase 3
Certolizumab
Johnson & JohnsonPhase 3
Jaktinib
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
ICP-332
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
VC005
JJiangsu vcare pharmaceutical technology co., LTD
Phase 3
Tilrekimig
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atopic Dermatitis16 trials
Show 13 more trials
Asthma6 trials
Show 3 more trials
Pregnancy1 trial
5 more indications
Ulcerative Colitis1 trial
Idiopathic Pulmonary Fibrosis1 trial
Liver1 trial
Unspecified1 trial
Tralokinumab for Dupilumab Failures
Active, not recruiting·PPsoriasis Treatment Center of Central New Jersey·Phase 4·NCT06773455·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tralokinumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- IL-13 Inhibitor[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company